Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
Open Access
- 28 August 2021
- journal article
- research article
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (5) , 1717-1732
Abstract
Introduction Clobetasol propionate (0.05% standard dose formulation), a topical corticosteroid, leads to systemic side-effects like hypothalamic–pituitary–adrenal (HPA) axis suppression at doses as low as 2 g/day. The aim of this study was to evaluate HPA axis suppression, efficacy, and safety of clobetasol propionate (0.025%, formulation 5 and 13) versus currently marketed 0.05% cream in Indian patients with moderate-to-severe psoriasis. Methods In this phase 2a investigator-blinded study, patients aged ≥ 18 years with moderate-to-severe psoriasis were randomized 1:1:1 to receive clobetasol propionate 0.025% formulation 5, or 13, or 0.05% cream; twice daily for 28 days. Safety endpoints included adrenocorticotropic hormone (ACTH) test results at day 28 (primary), and local tolerability at each visit (burning/stinging/pruritus, secondary). Efficacy endpoints included Psoriasis Global Assessment (PGA) score. Results Overall, 88 patients received clobetasol propionate 0.025% formulation 5 and 13 (n = 29 for both) and 0.05% cream (n = 30). At day 28, the proportion of patients with an abnormal ACTH stimulation test (cortisol levels ≤ 18 µg/dl) was numerically lower in 0.025% formulations: 5 (20.7%) and 13 (17.2%) compared with 0.05% cream (30.0%), (p = 0.320). Decrease in burning/stinging /pruritus scores were comparable in all treatment groups and PGA success rates were higher with 0.025% formulations: 5 (38.9%) and 13 (36.8%) compared with 0.05% cream (30.8%). Conclusion Clobetasol propionate 0.025% could be an effective treatment for moderate-to-severe psoriasis compared with 0.05% cream, demonstrating comparable efficacy with a better systemic safety profile. Trial Registration Number REF/2018/01/016779.Keywords
Funding Information
- Dr Reddy's Laboratories Pvt Ltd
This publication has 20 references indexed in Scilit:
- Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analysesBritish Journal of Dermatology, 2013
- Evaluation of the pituitary-adrenal axis function in patients on topical steroid therapyJournal of the American Academy of Dermatology, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- Psoriasis in India: Prevalence and patternIndian Journal of Dermatology, Venereology and Leprology, 2010
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Psoriasis: epidemiology, clinical features, and quality of lifeAnnals of the Rheumatic Diseases, 2005
- Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasisJournal of the European Academy of Dermatology and Venereology, 1998
- Topical clobetasol-17-propionate: Review of its clinical efficacy and safetyJournal of the American Academy of Dermatology, 1986
- Clobetasol Propionate Cream Versus Halcinonide Cream in PsoriasisInternational Journal of Dermatology, 1986